Navigation Links
Genzyme to Build New R&D Center in Beijing
Date:4/22/2008

, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements regarding Genzyme's business plans and strategies, including without limitation: the construction of an R&D facility in Beijing, the incorporation of environmentally sensitive design features and construction techniques into the facility, the commencement of construction of the facility, and the completion and opening of the facility in 2010. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: Genzyme's ability to obtain all required authorizations and permits to build the R&D facility; Genzyme's ability to utilize low impact environmental techniques and to incorporate environmentally sensitive design features into the facility; Genzyme's ability to construct the facility without delays resulting from customary design and construction risks; Genzyme's ability to validate, set-up and commence operations at the facility; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Annual Report on Form 10-K for the period ended December 31, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R), Synvisc(R), Thymoglobulin(R) and Cerezyme(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United St
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genzyme Provides Update on Myozyme(R) Manufacturing
2. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
3. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
4. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
5. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
6. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
7. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
8. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
9. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 2014 The global oligonucleotide synthesis ... 2019 from $1,070.7 million in 2014, growing at ... The global oligonucleotide synthesis market is categorized on ... users, and geography. The synthesized oligonucleotides segment is ... the oligonucleotide synthesis market during the forecast period, ...
(Date:8/31/2014)... Available spectra is similar for ... and cultivation of a wide range of plants. ... with proven patented and pending wide spectrum technology. ... in critical applications in contrast to growth spectra ... customers have a large variety of differently sized ...
(Date:8/30/2014)... (PRWEB) August 31, 2014 The ... a professional and in-depth study on the current ... Global and China. , The report provides a ... and industry chain structure. Global market analysis and ... focus on history, developments, trends and competitive landscape ...
(Date:8/29/2014)... The global companion diagnostics market ... It is expected to grow at a CAGR ... valued at $1.8 billion in 2013, according to ... , For more information regarding analysis details and ... research report, titled “Companion Diagnostics Market (Breast Cancer, ...
Breaking Biology Technology:9.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3
... The Quigley,Corporation (Nasdaq: QGLY ) today issued an ... Diabetic Peripheral Neuropathy by its wholly owned,subsidiary, Quigley Pharma, ... noted that over 100 subjects have been,enrolled, 52 subjects ... for the Phase IIB study designed to evaluate the ...
... VALLEY COTTAGE, New York, September 11 XTL,Biopharmaceuticals Ltd. ... hold a,conference call today, September 11, 2007, at 8:30 ... Bicifadine for the treatment of diabetic,neuropathic pain that was ... Bentsur, XTL,s Chief Executive Officer.,Participating on the call will ...
... DIEGO, Sept. 10 SGX Pharmaceuticals, Inc.,(Nasdaq: ... license and collaboration,agreement with Novartis focused on the ... of both first line and drug resistant,Chronic Myelogenous ... Novartis are progressing a number of,potential drug candidates, ...
Cached Biology Technology:Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy 2Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy 3Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2SGX Provides Update on BCR-ABL Collaboration 2SGX Provides Update on BCR-ABL Collaboration 3
(Date:9/1/2014)... every child in the U.S. undergoes a battery of ... sickle cell disease. Thousands of children born in the ... and die from the disease each year. , ... least some of those deaths. , A Post-Doctoral ... lab of George Whitesides, the Woodford L. and Ann ...
(Date:9/1/2014)... basic building block of DNAcould initiate fragile X syndrome, the most ... The Journal of Cell Biology . , ... on the X chromosome called fragile X mental retardation 1 ... men carry a so-called premutation, in which a series of DNA ... slightly longer than normal. These repeats are prone to even further ...
(Date:9/1/2014)... life without light. They emit echolocation sounds and use the ... or prey. In their brains, they have a spatial map ... at Technische Universitt Mnchen (TUM) has shown for the first ... , Closer objects appear larger , When ... number of activated neurons in its brain increases. As a ...
Breaking Biology News(10 mins):Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2
... , New research into the Earth,s paleoclimate history by ... Hansen suggests the potential for rapid climate changes this ... global warming is not abated. By looking at ... Hansen sought insight into a fundamental question raised by ...
... Gil and Rongchao Jin have successfully used NMR ... which could advance the development and use of ... Their approach offers a significant advantage over routine ... determine whether the nanoparticles exist in a both ...
... York, NYDecember 7, 2011Thanks to a new study ... able to diagnose in their offices non-periodic arrhythmiasnoninvasively ... arrhythmias include atrial and ventricular fibrillation, which are ... in some cases be life-threatening. Using ...
Cached Biology News:Paleoclimate record points toward potential rapid climate changes 2Paleoclimate record points toward potential rapid climate changes 3Paleoclimate record points toward potential rapid climate changes 4Carnegie Mellon researchers use NMR to determine whether gold nanoparticles exhibit 'handedness' 2Carnegie Mellon researchers use NMR to determine whether gold nanoparticles exhibit 'handedness' 3New Columbia engineering technique diagnoses non-periodic arrhythmias in a single heartbeat 2
Sphingosine 1-phosphate receptor Edg-1...
VAP-1 (S-13)...
Human SPARC-like 1 Biotinylated Affinity Purified PAb...
... at the 3, 3', 4, and 4' ... an internal standard for the quantification of ... spectrometry. PGE2 is one of the primary ... of the most widely investigated prostaglandins. Its ...
Biology Products: